NasdaqCM - Nasdaq Real Time Price USD
Jasper Therapeutics, Inc. (JSPR)
4.5600
+0.1900
+(4.35%)
At close: April 23 at 4:00:01 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -1.48 | -1.5 | -5.52 | -4.85 |
| Low Estimate | -1.8 | -1.94 | -8.1 | -7.85 |
| High Estimate | -1.29 | -1.19 | -3.03 | -1.85 |
| Year Ago EPS | -1.03 | -0.97 | -4.89 | -5.52 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 8 |
| Avg. Estimate | -- | -- | 4.89M | 1.42M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 44M | 10M |
| Year Ago Sales | -- | -- | -- | 4.89M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | -70.95% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.18 | -1.12 | -1.08 | -1.23 |
| EPS Actual | -1.03 | -0.97 | -1.24 | -1.62 |
| Difference | 0.15 | 0.15 | -0.17 | -0.39 |
| Surprise % | 12.88% | 13.26% | -15.38% | -31.95% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.48 | -1.5 | -5.52 | -4.85 |
| 7 Days Ago | -1.51 | -1.54 | -5.66 | -4.93 |
| 30 Days Ago | -1.54 | -1.57 | -5.67 | -5.15 |
| 60 Days Ago | -1.35 | -1.44 | -5.01 | -6.03 |
| 90 Days Ago | -1.22 | -1.28 | -4.62 | -6.24 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 2 | 1 |
| Up Last 30 Days | -- | 1 | 2 | 1 |
| Down Last 7 Days | 4 | 3 | 4 | 2 |
| Down Last 30 Days | 4 | 3 | 3 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| JSPR | -43.63% | -54.88% | -12.88% | 12.13% |
| S&P 500 | 6.85% | 4.67% | 8.41% | 14.16% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/11/2025 |
| Initiated | UBS: Buy | 2/13/2025 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 1/10/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/10/2025 |
| Maintains | RBC Capital: Outperform to Outperform | 1/9/2025 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 1/6/2025 |
Related Tickers
TIL Instil Bio, Inc.
20.52
+24.44%
ADIL Adial Pharmaceuticals, Inc.
0.7001
+3.29%
LCTX Lineage Cell Therapeutics, Inc.
0.4720
+9.82%
BCYC Bicycle Therapeutics plc
8.67
-0.69%
PTGX Protagonist Therapeutics, Inc.
46.16
+0.68%
ACRV Acrivon Therapeutics, Inc.
2.0000
-1.48%
RLMD Relmada Therapeutics, Inc.
0.6900
+82.54%
NMRA Neumora Therapeutics, Inc.
0.7109
+0.84%
TARA Protara Therapeutics, Inc.
4.2000
+6.60%
PYXS Pyxis Oncology, Inc.
1.0800
+5.88%